BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)
Earnings Call Insights: BioCardia (BCDA) Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final ...
